Wai Chun Bio-Technology (660) H1 2026 earnings summary

Executive summary

• Revenue surged 118.7% year-over-year to HK$352.2 million for the six months ended 31 December 2025, driven by increased market demand and consumption.

• Gross profit rose to HK$35.7 million, but gross margin declined to 10.1% from 13.1% due to higher costs.

• Loss attributable to owners narrowed to HK$5.9 million from HK$13.7 million year-over-year, mainly due to higher revenue and lower finance costs.

• No interim dividend was declared for the period.

Financial highlights

• Revenue: HK$352.2 million (up from HK$161.1 million year-over-year).

• Gross profit: HK$35.7 million (up from HK$21.1 million year-over-year).

• Gross margin: 10.1% (down from 13.1% year-over-year).

• Loss attributable to owners: HK$5.9 million (improved from HK$13.7 million loss year-over-year).

• Basic and diluted loss per share: HK cents 3.33 (improved from HK cents 7.97 year-over-year).

• Finance costs decreased by 51.4% to HK$5.0 million.

Outlook and guidance

• Plans to pursue strategic acquisitions in the PRC to capture new business opportunities and strengthen revenue and profit fundamentals.

• Actively identifying projects with growth potential for acquisitions or investments.

• Measures to improve working capital and cash flows include cost control and seeking new funding.